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Financial
Development milestone triggers $10 million payment for DURECT
DURECT Corporation (CA, USA) announced on 9 September 2019 that a long-acting injectable HIV investiR
technology, has triggered a $10 million milestone payment
gational product, employing its proprietary SABER
from Gilead Sciences (CA, USA). Under the terms of the collaborative agreement, which was signed in July 2019,
Gilead was granted the exclusive worldwide rights to develop and commercialize a long-acting injectable HIV
product using the SABER technology; an initial upfront payment to DURECT of $25 million was also part of
the deal. It is possible that achieving further milestones could trigger up to an additional $65 million as well as up
to an additional $70 million in sales-based milestones and tiered royalties on product sales. The agreement also
allows Gilead exclusive access to the SABER platform for development of therapeutics for the treatment of HIV
and Hepatitis B virus.
DURECT’s SABER proprietary technology is based on sucrose acetate isobutyrate and is a platform for developing extended-release, injectable formulations by allowing the active virus to be delivered in a biocompatible matrix
depot [1].

Polypid raises $50 million

The Israel-based company Polypid (Petah Tikva, Israel) announced on 5 September 2019 that they had successfully
raised $50 million in Series E1 funding, which they intend on using for the development of its pipeline and top
conduct, two Phase III, pivotal registration trials of its lead product, a doxycycline conjugate based on the company’s
proprietary PLEX™ (Polymer-Lipid Encapsulation matriX) platform.
The PLEX platform is based on a matrix made of alternating layers of lipids and biocompatible polymers
that encapsulate a therapeutic candidate between them and form a protected reservoir that facilitates localized
drug delivery at the target site. The company is developing a range of doxycycline products for the treatment of
surgical-site infections [2].

BrightInsight raises $25 million for its connected health software tool

Brightinsight (CA, USA), a spin-off from the medical device manufacturer Flex (CA, USA) announced on 11
September 2019 that it had raised €25 million for Series A funding, to enable the development of its novel software.
The software has been designed to enable pharmaceutical and medtech companies’ devices and drug-delivery systems
to communicate with each other. The company has engaged with the Federal US FDA and other regulatory bodies
to ensure that the technology created is regulatory compliant. Some early adopters of the technology include global
pharmaceutical companies, such as Novo Nordisk (London, UK) and Roche (Basel, Switzerland). Novo Nordisk
has selected BrightInsight to be its global digital health partner, in the development innovative for diabetes-care
products. BrightInsight has collaborated with Roche on the development of a novel web-based dosing calculator to
treat patients with hemophilia A [3].
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Collaborations & agreements
REGENXBIO to evaluate Clearside’s delivery platform for gene therapy candidate
On 4 September 2019, REGENXBio Inc (MD, USA) announced an option and license agreement for exclusive
worldwide rights to Clearside Biomedical Inc.’s (GA, USA) proprietary micro-injector delivery platform, for the
delivery of REGENRXBio’s RGX-314. RGX-314 is a novel, one-time sub-retinal treatment, which treats wet agerelated macular degeneration (AMD), diabetic retinopathy and other indications. Clearside’s SCS Microinjector™
has been developed for in-office and nonsurgical delivery of therapeutics into the suprachoroidal space.
RGX-314, REGENXBio’s lead candidate, is in clinical trials for indications, such as wet AMD and diabetic
retinopathy as well as other chronic retinal conditions that have, to date, been treated with antivascular endothelial
growth factor. RGX-314 inhibits vascular endothelial growth factor by employing a NAV AAV8 vector encoding
an antibody fragment. This modifies the pathway that typically leads to the formation of new leaky blood vessels
that can lead to retinal fluid accumulation and, ultimately, vision loss.
Phase IIb clinical trial results, thus far, indicated that subjects with wet AMD experienced dose-dependent
increases in protein expression levels across five cohorts tested [4].
Boehringer Ingelheim signs retinal disease deal with Inflammasome

Boehringer Ingleheim (Ingleheim, Germany) and Inflammasome Therapeutics Inc. (MA, USA) disclosed on
20 September 2019 that they had entered into a partnership to develop novel therapies for the treatment of
retinal diseases. Under the terms of the agreement, the companies will embark on a program of work, incorporating
Inflammasome’s intravitreal (IVT) drug-delivery technologies with compounds from Boehringer Ingelheim’s retinal
disease pipeline portfolio. Under the terms of the agreement disclosed, Inflammasome can potentially receive up to
$160 million up-front for R&D support and milestone payments. Additionally, the agreement contains provisions
for tiered royalties based on future commercial product sales and other commercialization milestones.
At the announcement of the agreement, CR Wood, from Boehringer Ingelheim, stated “Boehringer Ingelheim
is looking forward to developing Inflammasome’s novel technology for the delivery of our first-in-class retinal disease
compounds working jointly with Inflammasome’s highly experienced scientific team. This will enable us to develop a broad
range of novel therapy options for the many patients with retinal diseases waiting urgently for better and new therapy
options.”
IVT delivery platform is based on the delivery, via injection, of a long-acting degradable IVT implant to the
back of the eye [5].
Wize Pharma signs a deal with Copernicus for ophthalmic nonviral gene therapy technology

Wize Pharma Inc. (Hod Hasharon, Israel) announced on 11 September 2019 that it had signed a deal with the
privately held, gene therapy company Copernicus Therapeutics, Inc. (OH, USA) to allow its exclusive rights to
license, develop and commercialize products based on a nonviral gene therapy technology, which was developed by
Copernicus for the treatment of the rare, degenerative, inherited retinal disorder choroideremia.
Although full financial details of the agreement were not released, Wize has agreed to pay Copernicus an initial
one-time license fee and royalty payments in the high single or low double digits, depending on if net sale thresholds
are reached. In addition, Wize has also agreed to pay Copernicus to facilitate the completion of a Phase I/II clinical
study in subjects with choroideremia.
Copernicus’ nonviral delivery platform is based on vectors consisting of DNA nanoparticles (DNPs). The DNP’s
size (8–11 nm) allows them to diffuse safely and efficiently to the cell nucleus via the nuclear envelope. Studies
presented by the company have demonstrated localization of transfected gene expression to injection sites. The
company claims that the DNPs elicit fewer inflammatory, toxicity and immune responses when compared with
viral vector approaches [6].
University of Maryland grants Spherix option for anthrax-based ovarian cancer drug

Spherix Inc (NY, USA) announced on 17 September 2019 that it had an option to exclusively license an anthraxbased delivery technology platform from the University of Maryland (MD, USA) for the development of PrAg-PAS
for the treatment of ovarian cancer. The University of Maryland have granted an exclusive option based on its
proprietary technology (currently under patent application) that modifies the anthrax toxin protective antigen to
be activated by tumor cell-expressed membrane-anchored serine proteases, thus preferentially targeting cancer cells.
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Discussing the option, A Hayes, from Spherix, stated that “this invention from the University of Maryland,
Baltimore is ingenious. In simple terms, they have modified the anthrax toxin so that it kills cancer cells, but not other
cells. By using an elegant protein-engineering strategy, the inventors have hijacked the complex anthrax toxin-delivery
mechanism to create a highly efficient drug-delivery system specific to ovarian cancer cells. In mouse models tested, the
data demonstrated that tumor growth halted following treatment with PrAg-PAS and did not increase compared with the
control mice. The inventors also demonstrate that the drug is well-tolerated with no obvious adverse interactions. I believe
that PrAg-PAS has the potential to strongly enhance our anticancer clinical development program and we look forward
to completing our diligence on this promising anticancer drug” [7].
Nemaura Pharma & Sparsha announce exclusive strategic collaboration

On 27 September 2019, Nemaura Pharma Ltd (Loughborough, UK) announced that it was forming a strategic
partnership with Sparsha USA (CA, USA). The companies have agreed to collaborate on the development and
manufacture of transdermal patches and oral thin films at a commercial scale. Under the terms of the agreement
disclosed, Nemaura will develop transdermal therapeutic systems up to pilot clinical manufacture scale, for third
parties and internally funded programs, at its facilities in Loughborough. Sparsha USA will be the exclusive
commercial-scale manufacturer of products for the USA, Latin American and Canadian markets. Nemaura Pharma
has a pipeline of 20 drugs in development, of which five are formulated as transdermal patches. Financial details of
the agreement were not disclosed [8].
Kiel University & Hovione to develop high-dose inhalation formulations

The Institute of Pharmacy at Kiel University (Kiel, Germany) announced on 3 September 2019 that it had entered
into a collaborative agreement with the pharmaceutical company, Hovione (Loures, Portugal). Under the terms
of this 3-year agreement, the institute will have access to Hovione’s portfolio of large dose dry-powder inhalers to
investigate novel formulation approaches for high-dose inhalation applications.
Researchers at Kiel intend to utilize Hovione’s TwinMax and 8-shot inhalation devices, which are both large dose
dry-powder inhalers, to develop formulations containing soft pellets and nanocrystals for high-dose dry-powder
inhaler administration, using model drugs such as clarithromycin and rifampicin.
Speaking at the announcement of the collaboration, R Scherließ, from the Institute of Pharmacy at Kiel University
suggested, “In high-dose drug delivery, the key in inhaled formulation development is to create an active pharmaceutical
ingredient-rich formulation, for example, with as little as possible excipients, to deliver the required therapeutic dose with
the smallest amount of material as possible” [9].
Approvals & regulatory updates
FDA approves Novo Nordisk’s Oral Semaglutide, first glucagon-like peptide-1 in pill form

It was announced on 20 September 2019 that the FDA has approved Novo Nordisk’s (Bagsværd, Denmark)
Rybelsus, which contains semaglutide and is the first glucagon-like peptide-1 receptor agonist to be approved in
a pill form. According to the company, the once-a-day pill has been approved in two doses, 7 and 14 mg, and is
indicated for the treatment of Type 2 diabetes.
Speaking at the announcement of the approval, T Hobbs from Novo Nordisk explained, “People living with Type
2 diabetes deserve more innovation, research and support to help them achieve their individual (glycated hemoglobin)
goals. With Rybelsus, we have the opportunity to expand the use of effective glucagon-like peptide-1 receptor agonist
therapy, by providing adults with Type 2 diabetes an oral medication, which was previously only available as an injection,
to help with managing their blood sugar” [10].
FDA clears Insulet’s Omnipod DASH™ system as an alternate controller enabled infusion pump

Insulet Inc. (MA, USA) announced on 20 September 2019 that it has received clearance from the FDA for its
Omnipod DASH™ system, as an alternate controller enabled infusion pump. This clears the way for the company
to market its Omnipod DASH insulin management system, incorporating an automated insulin-delivery system,
such as the Insulet’s Omnipod Horizon™ system.
Clearance by the FDA for such a system required the company to prove that the pump was capable to reliably
and securely communicate with compatible, digitally connected devices and to be capable of receiving, executing
and confirming the commands issued by these devices.
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Discussing the announcement of the clearance, S Petrovic, from Insulet Inc. reported “The diabetes industry is
a dynamic and evolving landscape with technological and regulatory advancements, enabling more interoperability and
more patient choice in treatments and disease management. Omnipod DASH was designed with interoperability in mind
and we are thrilled to provide individuals with diabetes with the choice and flexibility to manage their diabetes on their
own terms. We commend the FDA’s interoperability efforts and look forward to working with the Agency as we continue
to deliver our robust innovation pipeline” [11].
R
IntelGenx announces resubmission of RIZAPORT
new drug application

It was announced on 26 September 2019 that IntelGenx Corp (QC, Canada) has submitted a new drug application
R
R
VersaFilm
to the FDA. This is a resubmission of the product in clinical trials for the treatment
for RIZAPORT
of migraine and follows on from the company receiving a complete response letter from the FDA in April 2019.
Issues cited in the complete response letter relate to the chemistry, manufacturing and controls section of the
new drug application and although the FDA requested additional information, no new bioequivalence study was
required by the regulatory authority before resubmission.
VersaFilm is a proprietary, buccal film designed to allow buccal or sublingual absorption, facilitated by rapid
disintegration, without the need for water that can have the potential for faster onset of action and increased
bioavailability. It allows for formulations to have an ease of administration for patients who have problems
swallowing, including pediatric and geriatric patients [12].
Orchestra BioMed announces FDA breakthrough device designation for Virtue sirolimus-eluting
balloon

Orchestra Biomed (PA, USA) announced on 17 September 2019 that it had secured breakthrough device designation by the FDA for its Virtue Sirolimus-Eluting Balloon (SEB) in the treatment of below-the-knee peripheral
artery disease. The company indicated that this breakthrough device designation was due to Virtue SEB being a
first-in-class drug/device combination product designed to facilitate the delivery of a sustained-release sirolimus
formulation, which can be employed during balloon angioplasty. The sustained release profile obtained is facilitated by bioabsorbable sub-micron particles, which encapsulate the sirolimus and allow for a drug elution profile,
comparable to commercially available drug-eluting Orchestra BioMed and its commercial partner Terumo (NY,
USA). These companies have planned a global clinical programme to gain regulatory approval for commercial sale
of Virtue SEB in multiple markets and further indications [13].
Clinical trials
Genetech announce positive Phase III results

Halozyme Therapeutics, Inc (CA, USA) announced positive results from a Phase III trial, evaluating fixed-dose
R
R
and Herceptin
on 13 September 2019. The clinical trial
subcutaneous combination of Genetech’s Perjeta
entitled ‘FeDeriCa’ investigated the subcutaneous administration of Perjeta and Herceptin (in a fixed-dose comR
drug-delivery technology in combination with the administration
bination) employing Halozyme’s ENHANZE
of intravenous chemotherapy. Patients with HER2-positive early breast cancer, demonstrated noninferior levels of
Perjeta compared with the standard treatment of intravenous infusion of Perjeta plus Herceptin and chemotherapy.
Halozyme’s ENHANZE drug delivery technology platform is based on a proprietary, patented, recombinant
human hyaluronidase enzyme (rHuPH20), which acts by degrading glycosaminoglycan hyaluronan and plays a
role in resistance to bulk fluid flow in the subcutaneous space. Thus, allowing for an increased level of therapeutics
that can be delivered subcutaneously [14].
Vascular Therapies announces positive data in Phase II/III trials

Vascular Therapies (NJ, USA) announced on 9 September 2019 that it had received positive initial data in Phase
II/III trials, using its proprietary sirolimus formulation, Sirogen™, for intraoperative, local, perivascular drug
delivery. The trials aim to investigate if Sirogen can improve arteriovenous fistula outcomes in dialysis patients.
The drug development program has received fast track status from the FDA and sirolimus also has ‘orphan drug’
designation for the dialysis of vascular access indications in both the USA and EU.
Sirogen is a novel bio-resorbable, collagen-based drug-delivery system containing sirolimus, which is implanted
during a surgical procedure and provides extended release of the sirolimus. The delivery system is designed to
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maintain its cylindrical shape without the need for sutures. This implant then facilitates an increase in vein
diameter [15].
Biohaven completes enrollment for pivotal Phase II/III trial of Vazegepant

Biohaven Pharmaceutical Holding Company Ltd (CT, USA) announced on 19 September 2019 that it had
completed enrollment for its pivotal Phase II/III trial of intranasally administered vazegepant, for the acute
treatment of migraine. Intranasal vazegepant employs the FDA-approved Aptar Pharma’s (Milton Keynes, UK)
unidose system.
The Phase II/III trial has been designed with end points related to a reduction of migraine associated symptoms
at 2 h post-dose and other clinically relevant measures including increased pain relief and the ability to return to
normal functioning.
Aptar Pharma’s unidose system is designed to deliver both liquid and powder formulations and has been designed
to deliver small and very precise amounts of active drug in a single nasal shot. Approved by the FDA for a number
of years, over 100 million units have been sold globally [16].
Early stage development
Positive preclinical results for Rapid Dose Technology’s film drug-delivery system

On 12 September 2019, Rapid Dose Therapeutics Corp. (Ontario, Canada) announced early preclinical results for
its QuickStrip™ technology. QuickStrip is an oral, dispersible, thin-film drug-delivery system designed to rapidly
deliver therapeutics directly to the bloodstream via sublingual or buccal routes.
A bioanalytical murine study has been designed to evaluate the oral-thin film of QuickStrip and caffeine for
onset time, bioavailability and effects on the central nervous system, compared with direct administration of the
active ingredient into the stomach via an oral gavage.
Discussing the results of the study M Upsdell stated, “We developed QuickStrip as a novel and versatile delivery system
with many applications, including nutraceuticals and pharmaceuticals, among others. We are excited to announce the
study results from University of Nevada, (Las Vegas, USA) which concluded that, for caffeine, Rapid Dose Therapeutics
(RDT) proprietary QuickStrip delivery method, produced greater bioavailability compared with gavage and speed of
uptake comparatively. Rapid Dose Therapeutics will continue to expand our research programs to further strengthen
our unique delivery leadership position. We are committed to providing consumers in the global medical and personal
product markets research-based validation that QuickStrip is a delivery system that is Quick, Convenient, Precise and
Discreet™” [17].
Ultra-long-acting tuneable biodegradable & removable controlled release implants for drug
delivery

A study by researchers at the University of North Carolina at Chapel Hill (NC, USA) was reported in Nature
Communications on 20 September 2019, which described an ultra-long-acting tuneable, biodegradable and removable polymer-based delivery injectable system, that demonstrates sustained drug delivery for up to 1 year for HIV
treatment or prophylaxis. The system was studied with six antiretroviral drugs and preclinical results indicated
that the drugs were released with concentrations above their protein-adjusted inhibitory concentration. It was also
concluded that the formulations allowed the drug candidates to retain their physical and chemical properties upon
release.
The formulation was composed of a ternary system: a biodegradable polymer (poly lactide co-glycolide), a
biocompatible and water-miscible, solvent N-methyl-2-pyrrolidone and the drug in a homogeneous solution, that
becomes a solid implant in situ when administered subcutaneously. The results indicated that it was possible to
design formulations that could produce release profiles, which revealed the release of actives over periods of up to
1 year with zero order release kinetics [18].
‘Nano-diamonds’ as a platform for diagnostic & therapeutic approaches for neurodegenerative
diseases

An article on 4 September 2019 described work carried out at the Max Planck Institute for Polymer Research
(MPI-P) (Munich, Germany) to create tiny diamonds, so-called ‘nano-diamonds’, which could act as a platform
for both the therapy and diagnosis of neurological diseases. Researchers have developed a method of coating
nano-diamonds with biocompatible serum albumin. These nanoparticles can be conjugated with drugs and initial
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preclinical work has indicated that the diamond-albumin-system can cross the blood–brain barrier both in vitro
and in murine studies.
Additionally, the researchers have modified the nano-diamond structure by introducing changes to the lattice
structure and creating defects that allow the nano-diamonds to be imaged using magnetic resonance tomographs,
opening the possibility of the particles being utilized as a diagnostic tool [19].
Alternative viral delivery of gene therapy developed

Researchers at Wisconsin Institute for Discovery at the University of Wisconsin–Madison (WI, USA) have developed
a novel nano-capsule that has the potential to deliver gene therapies. A gene-editing tool, CRISPR-Cas9, with
guide RNA was encapsulated by the researchers in a thin polymer shell and resulted in the formation of a capsule
approximately 25 nm in diameter. This nano-capsule can be modified by the addition of peptides and other
targeting functional groups on its surface. When the nano-capsule reaches its target cell its release of its payload is
triggered by glutathione. Due to their relatively short lifespan it is anticipated that the nano-capsules may reduce
unplanned genetic edits. The researchers claim that the nano-capsules are capable of producing robust gene editing
in vivo and in murine retinal pigment epithelium tissue and skeletal muscle after local administration [20].
Valeritas presents preclinical CBD Study using h-Patch™

Valeritas Holdings, Inc. (NJ, USA) announced on 19 September 2019 that data from its preclinical pharmacokinetic
study of a cannabidiol subcutaneous infusion, which employed its h-Patch™ system, had been accepted for a poster
presentation at the CannMed Conference (CA, USA) on 23 and 24 September 2019. Valertis’ h-Patch is an
R
Wearable Insulin Delivery device, to deliver all-in-one
FDA-approved technology already utilized in its V-Go
basal-bolus delivery of insulin for the treatment of patients with Type 2 diabetes. To date over 20 million V-Go
Insulin Delivery devices have been sold in the USA.
The h-Patch system has been designed to provide a continuous basal delivery rate over a period of up to 24 h via
subcutaneous delivery of the therapeutic. By avoiding the first-pass effect and eliminating peak/trough variations
of drug exposure, the device aims to prolong the half-life of the active ingredient delivered and minimizes the dose
necessary to achieve therapeutic levels of the active ingredient [21].
Researchers improve CRISPR-Cas9 delivery efficiency

A team of researchers from the Wake Forest Institute of Regenerative Medicine (NC, USA) reported that they had
successfully employed a lentiviral capsid-based bio-nanoparticle system to encapsulate a combination of the Cas9
protein and guide RNA. According to B Lu, this represents a significant advancement to the current state of the art
CRISPR-Cas9, as to date, the two components had to be delivered separately. According to the article, this research
builds on previously reported work by the group that developed a system capable of packaging up to 100 copies
of Cas9 mRNA in each lentivirus-like particle. This encapsulation was mediated via specific interactions between
aptamer and aptamer-binding proteins. The work reported that this lentiviral capsid-based bio-nanoparticle system,
facilitates more efficient packaging of Cas9/single guide RNA (sgRNA) ribonucleoprotein. The researchers claim
that by replacing the Tetraloop of the sgRNA scaffold with a com-aptamer, the functions of guide RNA are
preserved. This modified system demonstrated fast reduced off-target rates, thus improving the efficiency of the
delivery Cas9 ribonucleoproteins for transient Cas9 expression and improved genome editing efficiency [22].
Innovation Pharmaceuticals report successful formulation of oral Brilacidin tablets

Innovation Pharmaceuticals (MA, USA) announced on 16 September 2019 that its formulation partner, BDD
Pharma (Glasgow, UK) had completed nonclinical studies, which demonstrated that their oral dosage form met in
vitro specifications for selective colonic delivery of oral Brilacidin. This will allow Innovation Pharma to proceed
to the first clinical trial of oral Brilacidin for the treatment of Ulcerative Colitis. It is anticipated that this trial will
commence in December 2019 and will involve healthy volunteers in the UK.
The Brilacidin tablet design employs BDD Pharma’s proprietary OralogiK™ technology, which facilitates controlled release of a therapeutic active agent by programmed erosion of a time-dependent barrier layer, during transit
of the small intestine.
Brilacidin has recently completed a Phase II trial as an oral rinse formulation designed for the prevention of severe
oral mucositis in patients with head and neck cancer. Innovation Pharma intends to proceed into Phase III clinical
development for the oral rinse formulation. Also, the company recently reported positive results for a Phase II
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Proof-of-Concept trial treating patients locally with Brilacidin for ulcerative proctitis/ulcerative proctosigmoiditis.
Brilacidin was licensed for this indication to the company Alfasigma S.p.A. (Alfasigma, Italy) in July 2019 [23].
Delivery of RIPK4 small interfering RNA for bladder cancer therapy using natural halloysite
nanotubes

Researchers from the Central South University (Changsha, China) have reported successful in vitro delivery
of RIPK4 small interfering RNA using natural halloysite nanotubes in bladder cancer models (T24 bladder
cancer cells) in an article recently published in Science Advances. The nanotubes are composed of halloysite, an
aluminosilicate clay mineral, with the empirical formula Al2 Si2 O5 (OH)4 . The manufacture of these nanotubes
was achieved via a process of combining a high-speed shear homogenization step followed by a two-step uniform
viscosity centrifugation. The resultant nanotubes were typically in the 500 nm size range. Encapsulation of the
payload was achieved when negatively charged small interfering RNA was absorbed into the positively charged
lumen of the halloysites using vacuum impregnation methods.
The in vivo and in vitro data presented suggests that the encapsulated formulation enhanced the specific
knockdown of RIPK4 in bladder cancer cells and bladder tumors, which effectively suppressed tumor growth and
progression in a number bladder tumor models with no observable adverse effects or toxicity. The researchers claim
that the use of the nanotube encapsulated RIPK4 could be a novel therapeutic approach to treat bladder cancer [24].
Summary

The present industry update covers the period of September 2019, with information sourced primarily from
company press releases, scientific literature and various news websites. This month saw several collaborations
announced in the area of delivery of gene therapies, including collaborations between Wize Pharma and Copernicus
and REGENXBio and Clearside. Notable approvals by the FDA this month included Novo Nordisk’s Oral
Semaglutide and Insulet’s Omnipod DASH system as an infusion pump for insulin delivery. Halozyme announced
positive results from a Phase III trial evaluating fixed-dose subcutaneous combination of Genetech’s Perjeta and
Herceptin. Vascular Therapies announced that it had received positive initial data in Phase II/III trials using its
proprietary sirolimus formulation, Sirogen, which employs a novel bio-resorbable collagen-based drug delivery.
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